心室优势对Fontan手术远期结局的影响:一项25年单中心研究
该单中心25年队列纳入195例Fontan手术患者(右心室优势104例),围术期生存率相似(右心室优势98% vs 非右心室优势100%,P=0.51);中位随访4.5年,右心室优势组无移植生存率和无Fontan失败率均较低(10年估计值分别为80% vs 92%,P=0.04;73% vs 92%,P=0.04)。多因素分析示右心室优势是第二期死亡或心脏移植及Fontan失败的独立危险因素。
要点
- 右心室优势患者10年无移植生存率80%低于非右心室优势92%(P=0.04)。
- 右心室优势患者10年无Fontan失败率73%低于非右心室优势92%(P=0.04)。
- 右心室优势是第二期死亡或心脏移植及Fontan失败的独立危险因素。
核心结论
- 右心室优势与Fontan术后远期并发症相关,包括死亡、心脏移植和Fontan失败;该队列在围术期后可能受益于多学科Fontan门诊的加强监测。
研究设计与样本
- 回顾性单中心队列研究,纳入1998年10月至2022年2月在杜克大学医学中心(美国北卡罗来纳州达勒姆)接受Fontan手术的患者195例,其中右心室优势104例。
主要发现
- 围术期生存率右心室优势组98% vs 非右心室优势组100%(P=0.51)。
- 中位随访4.5年(四分位距0.3-9.8年),死亡或心脏移植比例为8.7%,Fontan失败率为11.8%。
- 10年无移植生存率右心室优势组80%(95%CI 70%-91%)vs 非右心室优势组92%(95%CI 83%-100%)(P=0.04)。
- 10年无Fontan失败率右心室优势组73%(95%CI 62%-86%)vs 非右心室优势组92%(95%CI 83%-100%)(P=0.04)。
- 多因素分析示右心室优势是第二期死亡或心脏移植的独立危险因素(参数估计值1.3±0.6;P=0.04)及Fontan失败的独立危险因素(参数估计值1.1±0.5;P=0.04),第一期无显著危险因素。
关键数值与推荐
- 主要结局为无移植生存率和Fontan失败(死亡、心脏移植、拆解、蛋白丢失性肠病或塑性支气管炎)。
- 次要结局包括住院时间和重症监护室停留时间。
- 采用Kaplan-Meier法比较不同心室优势的结局,多相参数风险危害分析识别主要结局的危险因素。
临床怎么用
- 作者认为,该队列在围术期后可能受益于多学科Fontan门诊的加强监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-term impact of ventricular dominance on Fontan outcomes is controversial. This study examined this issue in a 25-year cohort. METHODS: Patients undergoing the Fontan operation at a single institution (Duke University Medical Center, Durham, NC) from October 1998 to February 2022 were reviewed. Primary outcomes were transplant-free survival and Fontan failure (death, heart transplantation, takedown, protein-losing enteropathy, or plastic bronchitis). Secondary outcomes included hospital and intensive care lengths of stay. Kaplan-Meier methodology compared outcomes by ventricular dominance. Multiphase parametric risk hazard analysis identified risk factors for primary outcomes. RESULTS: There were 195 patients (104 right ventricular dominant) included in the study. Baseline characteristics were comparable. Perioperative survival was similar (right ventricular dominant, 98%; non-right ventricular dominant, 100%; P = .51). The proportion of patients experiencing death or heart transplantation was 8.7%, and the rate of Fontan failure was 11.8% during a median follow-up of 4.5 years (interquartile range, 0.3-9.8 years). Right ventricular-dominant patients had reduced transplant-free survival (10-year estimates: 80% [95% CI, 70%-91%] vs 92% [95% CI, 83%-100%]; P = .04) and freedom from Fontan failure (73% [95% CI, 62%-86%] vs 92% [95% CI, 83%-100%]; P = .04). Multiphase hazard modeling resolved 2 risk phases. The early phase spanned from surgery to approximately 6 months afterward. The late phase spanned from approximately 6 months after surgery onward. In multivariable analysis, right ventricular dominance was an independent risk factor for death or heart transplantation (parameter estimate, 1.3 ± 0.6; P = .04) and Fontan failure (1.1 ± 0.5; P = .04) during the second phase, with no significant first-phase risk factors. CONCLUSIONS: Right ventricular dominance was associated with long-term complications after Fontan procedures, including mortality, heart transplantation, and Fontan failure. This cohort may benefit from heightened surveillance in a multidisciplinary Fontan clinic after the perioperative period.
引用
- Thornton SW, Meza JM, Prabhu NK, et al. Impact of Ventricular Dominance on Long-Term Fontan Outcomes: A 25-year Single-institution Study. Ann Thorac Surg. 2022. PMID: 36543280. doi:10.1016/j.athoracsur.2022.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。